These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Dever DP; Bak RO; Reinisch A; Camarena J; Washington G; Nicolas CE; Pavel-Dinu M; Saxena N; Wilkens AB; Mantri S; Uchida N; Hendel A; Narla A; Majeti R; Weinberg KI; Porteus MH Nature; 2016 Nov; 539(7629):384-389. PubMed ID: 27820943 [TBL] [Abstract][Full Text] [Related]
3. Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells. Moiani A; Letort G; Lizot S; Chalumeau A; Foray C; Felix T; Le Clerre D; Temburni-Blake S; Hong P; Leduc S; Pinard N; Marechal A; Seclen E; Boyne A; Mayer L; Hong R; Pulicani S; Galetto R; Gouble A; Cavazzana M; Juillerat A; Miccio A; Duclert A; Duchateau P; Valton J Nat Commun; 2024 Jun; 15(1):4965. PubMed ID: 38862518 [TBL] [Abstract][Full Text] [Related]
4. Gene expression in blood from an individual with β-thalassemia: An RNA sequence analysis. Taghavifar F; Hamid M; Shariati G Mol Genet Genomic Med; 2019 Jul; 7(7):e00740. PubMed ID: 31134759 [TBL] [Abstract][Full Text] [Related]
5. Targeted Integration of Inducible Caspase-9 in Human iPSCs Allows Efficient Lipus A; Janosz E; Ackermann M; Hetzel M; Dahlke J; Buchegger T; Wunderlich S; Martin U; Cathomen T; Schambach A; Moritz T; Lachmann N Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260086 [TBL] [Abstract][Full Text] [Related]
6. Exploring the bone marrow micro environment in thalassemia patients: potential therapeutic alternatives. Li Z; Yao X; Zhang J; Yang J; Ni J; Wang Y Front Immunol; 2024; 15():1403458. PubMed ID: 39161767 [TBL] [Abstract][Full Text] [Related]
7. In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery. Bahal R; Ali McNeer N; Quijano E; Liu Y; Sulkowski P; Turchick A; Lu YC; Bhunia DC; Manna A; Greiner DL; Brehm MA; Cheng CJ; López-Giráldez F; Ricciardi A; Beloor J; Krause DS; Kumar P; Gallagher PG; Braddock DT; Mark Saltzman W; Ly DH; Glazer PM Nat Commun; 2016 Oct; 7():13304. PubMed ID: 27782131 [TBL] [Abstract][Full Text] [Related]
8. Transcriptome Analyses of β-Thalassemia -28(A>G) Mutation Using Isogenic Cell Models Generated by CRISPR/Cas9 and Asymmetric Single-Stranded Oligodeoxynucleotides (assODNs). Li J; Zhou Z; Sun HX; Ouyang W; Dong G; Liu T; Ge L; Zhang X; Liu C; Gu Y Front Genet; 2020; 11():577053. PubMed ID: 33193694 [TBL] [Abstract][Full Text] [Related]
11. Expression, functional mechanism and therapy application of long noncoding RNA in Pan Y; Xu L; Huang H Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):252-257. PubMed ID: 35545416 [TBL] [Abstract][Full Text] [Related]
12. Precise correction of a spectrum of β-thalassemia mutations in coding and non-coding regions by base editors. Prasad K; Devaraju N; George A; Ravi NS; Paul J; Mahalingam G; Rajendiran V; Panigrahi L; Venkatesan V; Lakhotiya K; Periyasami Y; Pai AA; Nakamura Y; Kurita R; Balasubramanian P; Thangavel S; Velayudhan SR; Newby GA; Marepally S; Srivastava A; Mohankumar KM Mol Ther Nucleic Acids; 2024 Jun; 35(2):102205. PubMed ID: 38817682 [TBL] [Abstract][Full Text] [Related]
13. Generation and Characterization of Induced Pluripotent Stem Cells Carrying An ASXL1 Mutation. Wang W; Zhang X; Li Y; Shen J; Li Y; Xing W; Bai J; Shi J; Zhou Y Stem Cell Rev Rep; 2024 Jun; ():. PubMed ID: 38884929 [TBL] [Abstract][Full Text] [Related]
14. A promising iPS-based single-cell cloning strategy revealing signatures of somatic mutations in heterogeneous normal cells. Miao X; Li Y; Zheng C; Wang L; Jin C; Chen L; Mi S; Zhai W; Wang QF; Cai J Comput Struct Biotechnol J; 2020; 18():2326-2335. PubMed ID: 32994891 [TBL] [Abstract][Full Text] [Related]
15. Modeling the rare diseases process in dish. Tang W Intractable Rare Dis Res; 2018 May; 7(2):72. PubMed ID: 29862146 [TBL] [Abstract][Full Text] [Related]
16. Correction to: Modeling CADASIL vascular pathologies with patient-derived induced pluripotent stem cells. Protein Cell; 2024 May; 15(5):393. PubMed ID: 38113127 [No Abstract] [Full Text] [Related]
17. Correction: Cost of gene therapy. Harrison PT; Friedmann T Gene Ther; 2024 Mar; 31(3-4):195-196. PubMed ID: 38172433 [No Abstract] [Full Text] [Related]
18. β-Thalassemia gene editing therapy: Advancements and difficulties. Hu J; Zhong Y; Xu P; Xin L; Zhu X; Jiang X; Gao W; Yang B; Chen Y Medicine (Baltimore); 2024 May; 103(18):e38036. PubMed ID: 38701251 [TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia. Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144 [TBL] [Abstract][Full Text] [Related]
20. Genetic Manipulation Strategies for β-Thalassemia: A Review. Zakaria NA; Bahar R; Abdullah WZ; Mohamed Yusoff AA; Shamsuddin S; Abdul Wahab R; Johan MF Front Pediatr; 2022; 10():901605. PubMed ID: 35783328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]